Competition & Markets Authority – Investigation Into Vifor Pharma Concludes With Commitments

Competition & Markets Authority ("CMA") concluded its investigation into suspected abuse of dominant position by Vifor Pharma ("Vifor") in the supply of intravenous iron for UK National Health Service ("NHS") patients by accepting the undertaking's commitments.

The CMA found that Vifor had a dominant position in the market for the supply of high-dose intravenous iron for the period 2010-2024 and had raised serious competition concerns that Vifor had abused its dominant position to disseminate misleading information about the safety and efficacy of its competitor Pharmacosmos' Monofer product in order to create perceptions in favor of its own product Ferinject. In this context, it was stated that Vifor had an unfair advantage over its competitor in its commercial communications to healthcare professionals and that this created a cost burden on the NHS.